Feverfew: Choosing a Product and Dosing
With most supplements, choosing a product is a matter of price and taste. With feverfew it is arguably the whole question, because the difference between two bottles on the same shelf can be larger than the difference between the herb and a placebo.
That is not rhetoric. When pharmacy researchers bought commercial feverfew products and measured the parthenolide each one delivered at its own recommended daily dose, the range was 0.06 to 9.7 mg per day — a 160-fold difference (Nelson 2002). An earlier analysis using three independent methods found that some products sold as feverfew contained no detectable parthenolide at all (Heptinstall 1992).
So this page is the practical one. What the different forms are, what the numbers on a label mean, which numbers are useless, how the doses used in trials translate, how long to take it, and how to stop.
Table of Contents
- How Bad the Variability Actually Is
- The Forms of Feverfew
- Reading a Feverfew Label
- The Doses Actually Used in Trials
- Translating a Trial Dose to a Real Product
- Chewing Fresh Leaves: Mouth Ulcers and Uncontrolled Dose
- Storage, Shelf Life and Degradation
- How Long to Take It, and How to Judge
- Stopping and Post-Feverfew Syndrome
- Combination Products and Stacking
- What It Costs and How It Compares
- Cautions and Interactions
- Key Research Papers
- Connections
- Featured Videos
How Bad the Variability Actually Is
Three published analyses define the problem, and each deserves to be read in its own numbers.
Nelson 2002 — the 160-fold finding
Researchers bought commercial feverfew products and analysed them by high-performance liquid chromatography (HPLC) (Nelson 2002). What they found:
- The weight of feverfew leaf per capsule broadly matched the label, ranging from 25 to 500 mg. So manufacturers were putting in roughly what they claimed, by weight.
- Parthenolide per dosage form varied 150-fold, from 0.02 mg to 3.0 mg.
- Expressed as a percentage of the material, parthenolide varied 5.3-fold, from 0.14% to 0.74%.
- Following each product's own label directions, daily leaf intake would range from 225 to 2,246 mg (a 10-fold spread) and daily parthenolide intake from 0.06 to 9.7 mg — a 160-fold spread.
The 160-fold figure is the product of two multiplying problems: the herb varies in potency, and the labels recommend very different amounts of it. A consumer following instructions faithfully has no way to know which end of that range they are on.
Heptinstall 1992 — some products had none
An international team measured parthenolide by HPLC, nuclear magnetic resonance (NMR) spectroscopy, HPLC of a derivative, and a platelet bioassay. All four methods agreed with each other, so the numbers are trustworthy. Their findings (Heptinstall 1992):
- Authenticated Tanacetum parthenium grown in the UK had high parthenolide in leaves, flowering tops and seeds, and low levels in stalks and roots. What part of the plant goes into the capsule matters.
- Parthenolide levels in powdered leaf fell during storage.
- Purported feverfew products “varied widely in their parthenolide content and in some products parthenolide was not detected.”
- Their recommendation, more than thirty years ago: manufacturers should use parthenolide measurement as a means of standardisation and quality control.
Two further wrinkles worth knowing. Feverfew is occasionally misidentified: Tanacetum vulgare (tansy) and Anthemis or Matricaria species look broadly similar to a non-botanist, and tansy contains thujone, which is genuinely toxic. And because parthenolide degrades, the same bottle is not the same product a year later — a dermatology group re-analysing a feverfew cream after two years found no parthenolide remaining (Paulsen 2010).
Jin 2008 — label claims not met
A 2008 laboratory study measured parthenolide in several commercial feverfew extracts with a validated HPLC assay. “No commercial feverfew extracts tested contained the label claimed parthenolide,” and even different batches from the same manufacturer had significantly different parthenolide content (Jin 2008). A parthenolide figure on a label is therefore a claim, not a guarantee.
The Forms of Feverfew
| Form | What it is | Evidence and notes |
|---|---|---|
| Supercritical CO2 extract (the type used in the Diener and Pfaffenrath trials) | Extraction with pressurised carbon dioxide to a reproducible specification; no solvent residue, and the process is controllable batch to batch | The form with the best trial evidence. This is the extract type used in the Diener 2005 trial, which reported a small benefit |
| Standardised dried-leaf capsules | Milled leaf with a stated parthenolide percentage, usually 0.2–0.7% | Closest to what the positive 1980s trials used, with the quality number the 1980s trials lacked |
| Unstandardised dried-leaf capsules | Milled leaf, weight on the label, no parthenolide figure | A lottery. This is the category the 160-fold finding came from |
| Freeze-dried leaf | Leaf dried at low temperature, which better preserves heat-sensitive chemistry | Used in the 1985 trial. Plausible on chemistry grounds; still needs a parthenolide figure to be meaningful |
| Alcoholic extract / tincture | Ethanol extraction, sold as liquid or dried onto a carrier | The one preparation with a clearly negative trial (De Weerdt 1996, 0.5 mg parthenolide/day). Not disqualifying, but not encouraging |
| Tea from dried leaf | Hot water infusion | Parthenolide is poorly water-soluble, so a tea delivers little of it. A water extract does show some activity in the laboratory (Recinella 2020), but this is not what was tested clinically |
| Fresh leaves, chewed | The traditional method: two or three small leaves daily | The route most associated with mouth ulcers, and the dose is completely uncontrolled |
| Sublingual combination products | Feverfew plus ginger, taken at the onset of an attack | A different intervention with a different purpose — acute, not preventive, and not feverfew alone |
| Topical parthenolide-depleted extract | Skincare ingredient with parthenolide deliberately removed to avoid sensitising skin | A cosmetic ingredient, unrelated to migraine, designed to have the parthenolide removed. In a 2010 patch-test study, four of seven feverfew-allergic patients tested positive to one of two creams containing such an extract, with reactions linked to simultaneous positive reactions to parthenolide; the authors concluded such products “may elicit positive patch test reactions in feverfew-sensitive patients” (Paulsen 2010) |
Reading a Feverfew Label
Six label elements, in order of how much they tell a reader.
| Label element | What a good product states | Red flag |
|---|---|---|
| Parthenolide in milligrams | “0.5 mg parthenolide per capsule” an absolute number you can multiply by the daily dose (a 2008 analysis found no commercial extract tested met its labelled parthenolide content) | No parthenolide figure anywhere on the label |
| Parthenolide percentage | “Standardised to 0.7% parthenolide” useful, but only alongside the capsule weight | “Standardised extract” with no marker compound named |
| Species and plant part | Tanacetum parthenium, leaf or aerial parts | “Feverfew” with no Latin binomial; “whole herb” (stalks and roots have little parthenolide) |
| Extract type | “Supercritical CO2 extract” or “dried leaf powder” stated plainly | “10:1 extract” alone. A ratio is not a dose and cannot be compared to anything |
| Third-party testing | A named testing programme, with a certificate of analysis available on request | A “GMP” (good manufacturing practice) logo and nothing else |
| Expiry and batch | A real expiry date and lot number — parthenolide degrades, so these matter more than usual | No date; bulk packaging bought years' worth at a time |
The single most useful question: can you work out how many milligrams of parthenolide you will swallow per day? If the label does not let you calculate that, you cannot compare the product with any study, and you cannot compare it with the bottle you bought last year. That is the practical meaning of the 160-fold finding.
A worked example. A capsule of 380 mg dried leaf standardised to 0.5% parthenolide contains 380 × 0.005 = 1.9 mg parthenolide. Two capsules daily is 3.8 mg/day — near the top of what the Nelson survey found in real products, and well above the 0.5 mg/day used in the negative Dutch trial. Whether more is better is unproven, but at least you know where you stand.
The Doses Actually Used in Trials
These are the doses the trials used:
| Trial | Preparation | Dose | Duration | Result |
|---|---|---|---|---|
| Diener 2005 | Supercritical CO2 extract | 6.25 mg three times daily (18.75 mg/day) | 16 weeks | 0.6 fewer attacks/month than placebo (P = 0.0456) |
| Pfaffenrath 2002 | Supercritical CO2 extract | 2.08, 6.25 or 18.75 mg three times daily | 12 weeks | Failed overall; 6.25 mg three times daily (t.i.d.) best in a 49-patient subgroup |
| Murphy 1988 | Dried feverfew leaf | One capsule daily | 4 months per arm, crossover | Fewer, less severe attacks |
| Johnson 1985 | Freeze-dried leaf powder | Capsules replacing habitual fresh-leaf use | Several months | Placebo group deteriorated |
| De Weerdt 1996 | Dried alcoholic extract | One capsule daily, 0.5 mg parthenolide | 9 months, crossover | No effect |
| Pattrick 1989 (arthritis) | Dried chopped feverfew | 70–86 mg once daily | 6 weeks | No benefit in rheumatoid arthritis |
The commonly quoted range of 50–150 mg of dried leaf per day is a fair summary of the dried-leaf studies. It is not a dose for a CO2 extract, where 18.75 mg per day was the effective amount — because that is concentrated material, not leaf.
A 2020 systematic review of 19 randomised, controlled trials of single herbs for migraine found that “findings on the efficacy of feverfew were mixed,” with “positive, albeit limited evidence for butterbur,” and noted that “the risk of bias was high for many studies” (Lopresti 2020).
Translating a Trial Dose to a Real Product
Three points from the trial record.
1. A milligram figure does not carry between preparations. 18.75 mg of the trial CO2 extract and 18.75 mg of dried leaf powder are not comparable in any way. Extracts concentrate; leaf does not. A number only means something against the form it was measured in.
2. A stated parthenolide figure is the only common currency, and labels have not always met it. It is the only figure that means the same thing across preparations, but a 2008 analysis found that no commercial feverfew extract tested contained the parthenolide its label claimed (Jin 2008). For orientation, the negative Dutch trial delivered 0.5 mg/day; commercial products in the Nelson survey delivered 0.06–9.7 mg/day; the phase I safety trial, in people with cancer, went to 4 mg/day with no significant toxicity and no maximum tolerated dose reached, and at doses up to 4 mg there was “not detectable concentration in the plasma” (detection limit 0.5 ng/mL) (Curry 2004).
3. On a product that states nothing useful, the label dose is arbitrary. It cannot be matched to any trial dose, and going above it on an unquantified product adds an unknown amount.
One more honest note. There is no established dose-response relationship for feverfew in humans. The one study designed to find one — Pfaffenrath 2002 — failed to demonstrate it in its main analysis. Higher parthenolide is not proven to be better. It is simply the only variable you can measure.
Chewing Fresh Leaves: Mouth Ulcers and Uncontrolled Dose
The traditional British method — two or three fresh leaves in a sandwich each morning — is how feverfew's modern reputation began, and it is the method most associated with mouth ulcers.
- Mouth ulcers. This is feverfew's signature side effect, and it is overwhelmingly associated with chewing raw leaf. Painful aphthous-type ulcers, a sore or swollen tongue and lips, and sometimes temporary loss of taste. Cochrane's review of the trial data lists mouth ulcers as one of the two most common adverse events reported (Wider 2015). It is the direct local consequence of parthenolide's reactive chemistry meeting mucosal tissue.
- Completely uncontrolled dose. Parthenolide content varies with the plant, the season, the growing conditions and which leaf you pick. Three leaves is not a dose.
- Misidentification risk. Garden plants are not labelled. Tansy (Tanacetum vulgare) contains thujone and is not a substitute.
- Contact dermatitis. Handling the fresh plant can sensitise skin in susceptible people.
Capsules of dried leaf largely bypass the mouth-ulcer problem by not contacting the oral mucosa. Home-grown leaves that are dried and put into capsules avoid that mouth contact, but the dose is still unknown.
Storage, Shelf Life and Degradation
Parthenolide is chemically reactive, and reactive compounds do not last. The 1992 analysis found parthenolide levels fell during storage of powdered leaf material (Heptinstall 1992), and a feverfew cream re-analysed two years after purchase had no detectable parthenolide left (Paulsen 2010). Formulation work found that physical properties of commercial extracts relevant to product quality, such as moisture uptake and compactibility, “varied greatly with source” (Jin 2008).
What follows from this:
- Large quantities degrade before they are used. A year's supply bought on offer is a year's supply degrading in the cupboard.
- The expiry date matters more than usual — more meaningful for feverfew than for a mineral supplement, which does not degrade at all.
- Cool, dark and dry storage. Not above the stove, not on a sunny windowsill, not in a steamy bathroom.
- The desiccant sachet in the bottle absorbs moisture while the lid is closed.
- A product that suddenly seems to stop working may simply be old. With feverfew, an old bottle is a genuinely plausible explanation.
How Long to Take It, and How to Judge
Feverfew is a preventive. That dictates everything about the schedule.
- Every day in the trials, whether or not a headache was present. It has never been tested any other way.
- Food and stomach upset. Gastrointestinal upset is the other common mild side effect, and taking it with food is the usual suggestion for reducing it.
- Divided doses. The best trial used three times daily.
- Time before judging. Diener's trial ran 16 weeks and measured the effect during treatment months two and three, deliberately excluding the first month.
- A headache diary with a baseline. Every trial used a 4-week baseline because migraine frequency naturally fluctuates. Without a baseline, a good month is easily misattributed.
- A success criterion set in advance — for example, at least two fewer migraine days per month — is what makes a personal trial readable.
The expectations the data support: the best trial produced 0.6 fewer attacks per month than placebo. If your realistic hope is “perhaps one fewer attack most months, possibly more if I turn out to be a responder,” feverfew may satisfy you. If your hope is to stop having migraines, it will not.
Stopping and Post-Feverfew Syndrome
This is the part people miss, and it is important enough to have its own name.
Long-term users who stopped suddenly have described rebound effects. Regular users who quit suddenly have described a withdrawal cluster — rebound headache often worse than baseline, anxiety, poor sleep, fatigue, and muscle and joint stiffness — known as post-feverfew syndrome. The first controlled trial documented exactly this: habitual users switched to placebo had significantly more frequent and severe headache, nausea and vomiting, with unpleasant effects emerging in the early months (Johnson 1985).
One consequence: rebound headache after stopping can look like proof that feverfew was working, when it is a withdrawal effect. Details are in Side Effects and Post-Feverfew Syndrome.
Combination Products and Stacking
Feverfew appears in a lot of blends. A few notes:
- Feverfew plus ginger, sublingual. Tested for acute treatment, not prevention. The 2011 pilot in 60 patients treating 221 attacks reported 32% pain-free at two hours versus 16% on placebo (Cady 2011), following a smaller 2005 open study (Cady 2005). Tested only for early treatment of an attack; it is not a preventive, and not feverfew alone.
- Feverfew plus willow bark. An open-label uncontrolled study reported benefit (Shrivastava 2006). Open-label, uncontrolled studies of headache remedies routinely look positive and routinely fail when blinded. Willow bark is also salicylate-based, which compounds the bleeding caution.
- Feverfew in a proprietary “migraine blend.” If the label does not disclose per-ingredient amounts, you cannot know your feverfew dose — and given the variability data, an undisclosed feverfew dose is close to no information at all.
- Stacking with magnesium or riboflavin is common; when several things change at once, there is no way to tell which one helped.
- Adding feverfew to a prescription preventive adds its antiplatelet effect to the regimen and changes the headache pattern the prescriber is tracking.
What It Costs and How It Compares
Feverfew is inexpensive. Basic dried-leaf capsules typically cost a few pounds or dollars a month; a standardised or CO2 extract is more, but rarely dramatically so. Against a documented net benefit of 0.6 attacks per month in the best trial, and an adverse-event rate no higher than placebo, it is a low-cost, well-tolerated preventive with a small expected effect, and that effect can only be judged with a product whose contents can be quantified.
Where it falls short: it does not replace evaluation of frequent or disabling migraine, or effective prescription prophylaxis; and an unquantified capsule bought purely on price is the version of feverfew most likely to be one of the products containing almost no parthenolide.
Cautions and Interactions
- Pregnancy and breastfeeding: a traditional warning and one rat screen. Traditional emmenagogue reputation, and the only experimental reproductive screen (rats, 839 mg/kg) produced smaller fetuses and embryotoxicity in culture, with the authors calling for a full study (Yao 2006). Insufficient data for breastfeeding.
- Asteraceae (Compositae) allergy. Cross-reactivity with ragweed, chrysanthemum, marigold, daisy and chamomile. Parthenolide is a recognised contact sensitiser (Paulsen 2010).
- Anticoagulants and antiplatelet drugs. Feverfew extracts inhibit platelet aggregation and granule secretion in laboratory studies (Heptinstall 1985; Groenewegen 1990) and altered platelet responses have been seen in feverfew users (Biggs 1982). Taken with warfarin, aspirin, clopidogrel, direct oral anticoagulants (DOACs), high-dose fish oil or other antiplatelet supplements, this effect adds to theirs and raises the bleeding risk.
- Surgery and dental procedures. The antiplatelet effect matters for bleeding during an operation, and stopping suddenly is what long-term users have linked to post-feverfew syndrome. About two weeks before surgery is the stopping interval commonly given for herbs with an antiplatelet effect.
- Long-term use in coronary disease. A 2009 systematic review raised a theoretical concern about long-term feverfew use itself in people with coronary disease, because feverfew inhibits cyclooxygenase-2 (COX-2), the same enzyme some nonsteroidal anti-inflammatory drugs (NSAIDs) block; the authors wrote that longer-term studies will be needed to address it (Saranitzky 2009). No clinical harm has been demonstrated.
- Children. Not adequately studied.
- Existing mouth ulcers or oral disease. Chewing the leaf is the route linked to mouth ulcers; capsules avoid contact with the mouth.
Key Research Papers
Every identifier was verified live against NCBI E-utilities before being written here.
Product quality, content and stability
- Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. American Journal of Health-System Pharmacy. 2002;59(16):1527–1531 — PubMed PMID: 12185827 — The 150-fold per-capsule and 160-fold daily-dose findings.
- Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew: estimation of commercial and authenticated feverfew products. Journal of Pharmacy and Pharmacology. 1992;44(5):391–395 — PubMed PMID: 1359053 — Some products had no detectable parthenolide; levels fell during storage.
- Jin P, Madieh S, Augsburger LL. Selected physical and chemical properties of feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance. AAPS PharmSciTech. 2008;9(1):22–30. — PubMed PMID: 18446457 — No commercial extract tested contained its label-claimed parthenolide; batches from one manufacturer differed significantly.
- Paulsen E, Christensen LP, Fretté XC, Andersen KE. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients. Contact Dermatitis. 2010;63(3):146–150 — PubMed PMID: 20690937 — Four of seven feverfew-allergic patients reacted to one of two creams with a parthenolide-depleted extract; parthenolide undetectable in that cream re-analysed about two years later.
- Recinella L, Chiavaroli A, di Giacomo V, Antolini MD, Acquaviva A, Leone S, Brunetti L, Menghini L, Ak G, Zengin G, Di Simone SC, Ferrante C, Orlando G. Anti-Inflammatory and Neuromodulatory Effects Induced by Tanacetum parthenium Water Extract: Results from In Silico, In Vitro and Ex Vivo Studies. Molecules. 2020;26(1):22 — PubMed PMID: 33374525 — Laboratory and isolated-tissue activity of a water extract.
The dosing trials
- Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention. Cephalalgia. 2005;25(11):1031–1041. — PubMed PMID: 16232154
- Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a dose-response study. Cephalalgia. 2002;22(7):523–532 — PubMed PMID: 12230594 — The dose-response study that did not demonstrate a dose response overall.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. The Lancet. 1988;2(8604):189–192. — PubMed PMID: 2899663
- De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225–230 — PubMed PMID: 23195074 — Alcoholic extract, 0.5 mg parthenolide/day, no effect.
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal (Clinical Research Ed.). 1985;291(6495):569–573. — PubMed PMID: 3929876
- Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. 2015;4(4):CD002286 — PubMed PMID: 25892430 — Mouth ulcers and gastrointestinal complaints listed as the commonest adverse events.
- Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Annals of the Rheumatic Diseases. 1989;48(7):547–549 — PubMed PMID: 2673080 — 41 women, 70–86 mg dried chopped feverfew daily for six weeks, no apparent benefit.
- Lopresti AL, Smith SJ, Drummond PD. Herbal treatments for migraine: A systematic review of randomised-controlled studies. Phytotherapy Research. 2020;34(10):2493–2517 — PubMed PMID: 32310327 — Feverfew findings mixed across 19 trials of single herbs.
Safety, tolerability and combinations
- Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs. 2004;22(3):299–305 — PubMed PMID: 15122077 — Up to 4 mg parthenolide daily was well tolerated with no dose-limiting toxicity; parthenolide was not detectable in plasma.
- Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. The Lancet. 1985;1(8437):1071–1074. — PubMed PMID: 2860288
- Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. Journal of Pharmacy and Pharmacology. 1990;42(8):553–557 — PubMed PMID: 1981582
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. The Lancet. 1982;2(8301):776. — PubMed PMID: 6125851
- Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reproductive Toxicology. 2006;22(4):688–693. — PubMed PMID: 16781113
- Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache. 2011;51(7):1078–1086. — PubMed PMID: 21631494
- Cady RK, Schreiber CP, Beach ME, Hart CC. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Medical Science Monitor. 2005;11(9):PI65–PI69 — PubMed PMID: 16127373 — Open-label.
- Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clinical Drug Investigation. 2006;26(5):287–296. — PubMed PMID: 17163262
- Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements. 2009;6(2):91–103. — PubMed PMID: 22435410
PubMed Topic Searches
- PubMed: Feverfew standardisation and parthenolide content
- PubMed: Herbal supplement quality and adulteration
- PubMed: Supercritical CO2 extraction of botanicals
- PubMed: Parthenolide stability and storage
- PubMed: Tansy, thujone and misidentification
- PubMed: Feverfew and anticoagulant interactions
- PubMed: Herbal medicines and perioperative bleeding
- PubMed: Headache diaries in prophylaxis trials
Connections
- All Herbs
- Feverfew Benefits — hub
- Migraine Prevention — what the trials found
- How Parthenolide Works
- Side Effects and Post-Feverfew Syndrome
- Feverfew — the main herb page
- Migraine
- Neurology
- Butterbur — where product quality is a safety issue, not just an efficacy one
- Ginger — the partner herb in sublingual combinations
- Chamomile